The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Neuromyelitis Optica Spectrum Disorder Market Expected To Change From 2026 To 2030?
The market size for neuromyelitis optica spectrum disorder has experienced strong growth in recent years. It is projected to increase from $2.54 billion in 2025 to $2.76 billion in 2026, at a compound annual growth rate (CAGR) of 8.4%. The expansion observed in the historic period can be attributed to several factors, including increasing awareness of nmosd, the early development of immunosuppressive treatments, the initial use of corticosteroids for controlling flares, the adoption of imaging for differential diagnosis, and the rising identification of aqp4 antibodies.
The neuromyelitis optica spectrum disorder market is set to experience substantial growth in the upcoming years, projected to reach $3.76 billion by 2030, at a compound annual growth rate (CAGR) of 8.1%. This expansion during the forecast period can be ascribed to a rising demand for targeted biologics, an increase in the development of mog-antibody therapies, the proliferation of advanced diagnostic platforms, heightened investment in autoimmune research, and the creation of next-generation immunotherapy solutions. Significant trends for the forecast period encompass the increasing adoption of monoclonal antibody therapies, greater utilization of advanced imaging techniques for prompt diagnosis, an escalating need for plasma exchange and immunoglobulin therapy, the expansion of aqp4-positive and mog-antibody testing, and a heightened focus on preventing relapses and ensuring long-term disease management.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22072&type=smp
What Key Factors Are Affecting The Neuromyelitis Optica Spectrum Disorder Market Demand?
The increasing prevalence of multiple sclerosis is projected to drive the expansion of the neuromyelitis optica spectrum disorder market moving forward. Multiple sclerosis is a chronic autoimmune condition that affects the central nervous system, leading to inflammation, nerve damage, and various neurological symptoms. The growing occurrence of multiple sclerosis can be attributed to improved diagnostic techniques, environmental influences, and genetic predisposition. Advances in medical imaging, such as MRI, have facilitated earlier and more accurate diagnoses, resulting in a visible rise in cases. As more individuals are diagnosed with MS, awareness of neurological autoimmune diseases increases, leading to enhanced diagnostic methods and a greater recognition of neuromyelitis optica spectrum disorder. For instance, in May 2024, data from the Multiple Sclerosis Trust, a UK-based national charity, indicated that the UK records approximately 7,100 new multiple sclerosis cases annually, with around 135 persons diagnosed with MS each week. Therefore, the rising prevalence of multiple sclerosis is a key driver for the growth of the neuromyelitis optica spectrum disorder market.
What Are The Different Segment Types In The Neuromyelitis Optica Spectrum Disorder Market Segment Breakdown?
The neuromyelitis optica spectrum disorder market covered in this report is segmented –
1) By Type: Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies, Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies
2) By Diagnosis: Imaging Tests, Magnetic Resonance Imaging (MRI), Blood Tests, Other Diagnosis
3) By Treatment Type: C5 Protein Inhibitor, Monoclonal Antibodies, Plasma Exchange Therapy, Corticosteroids, Immunoglobulin Therapy, Medication, Other Treatment Types
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies: Relapsing NMOSD With AQP4-IgG, Monophasic NMOSD With AQP4-IgG, Severe Optic Neuritis With AQP4-IgG, Longitudinally Extensive Transverse Myelitis (LETM) With AQP4-IgG
2) By Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies: NMOSD With Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies (MOG-IgG), Seronegative NMOSD, Idiopathic NMOSD Cases, NMOSD Associated With Other Autoimmune Disorders
What Trends Are Influencing Changes In The Neuromyelitis Optica Spectrum Disorder Market?
Leading companies in the neuromyelitis optica spectrum disorder market are concentrating on creating novel products, such as long-acting complement inhibitors, aimed at boosting treatment effectiveness and bettering patient outcomes. These inhibitors are therapeutic agents designed to suppress the complement system over an extended period, thereby averting inflammation and nerve damage in neuromyelitis optica spectrum disorder (NMOSD). Their function is to reduce the frequency of relapses and facilitate enduring disease management. As an example, in March 2024, Alexion Pharmaceuticals, a US-based biopharmaceutical firm, and AstraZeneca, a UK-based pharmaceutical corporation, secured approval for ULTOMIRIS (ravulizumab-cwvz) to treat adults diagnosed with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). This particular approval establishes Ultomiris as the inaugural and sole long-acting C5 complement inhibitor accessible for NMOSD therapy. The basis for this decision stemmed from the Phase III CHAMPION-NMOSD trial, in which Ultomiris exhibited a 98.6% decrease in relapse risk over 73 weeks when compared against a placebo. During the trial, participants did not experience any relapses, and no novel safety issues emerged.
Who Are The Well-Known Companies In The Neuromyelitis Optica Spectrum Disorder Market?
Major companies operating in the neuromyelitis optica spectrum disorder market are F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd, Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc, Oregon Health & Science University, Arup Laboratories, Argenx SE, Metropolis Healthcare, Rush University Medical Center, Mitsubishi Tanabe Pharma Corporation, Viela Bio, Alexion Pharmaceuticals, Horizon Therapeutics plc, UCB S.A, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi S.A, Pfizer Inc, Eli Lilly and Company, Immune Pharmaceuticals Inc.
Get The Full Neuromyelitis Optica Spectrum Disorder Market Report:
Where Is The Neuromyelitis Optica Spectrum Disorder Market Most Concentrated Geographically?
North America was the largest region in the neuromyelitis optica spectrum disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromyelitis optica spectrum disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Neuromyelitis Optica Spectrum Disorder Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Neuromyelitis Optica Spectrum Disorder Market 2026, By The Business Research Company
Clinical Trial Imaging Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-trial-imaging-global-market-report
Nephrologists Market Report 2020 2030 Covid 19 Implications And Growth
Pediatric Clinical Trials Market Report
https://www.thebusinessresearchcompany.com/report/pediatric-clinical-trials-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model